Bruno Bragança

Bruno Bragança

Auto-generated profile, based on publicly available information

Bruno Bragança

Department of Cardiology, Unidade Local de Saúde Tâmega e Sousa (ULSTS), Penafiel, Portugal

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
BBBruno Bragança
Bruno Bragança
MTMaria Trêpa
Maria Trêpa
RSRaquel Santos
Raquel Santos
ISInês Silveira
Inês Silveira
MFMarta Fontes-Oliveira
Marta Fontes-Oliveira
MSMário Santos
Mário Santos
Bragança B, et al. J Cardiovasc Imaging. 2019 Sep;28:e25. https://doi.org/10.4250/jcvi.2019.0094

20 August 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
ACAlexandrina Campos-Martins
Alexandrina Campos-Martins
BBBruno Bragança
Bruno Bragança
Paulo Correia-de-SáPaulo Correia-de-Sá
Paulo Correia-de-Sá
Ana Patrícia Fontes-SousaAna Patrícia Fontes-Sousa
Ana Patrícia Fontes-Sousa
Heart failure with preserved ejection fraction (HFpEF) roughly represents half of the cardiac failure events in developed countries. The proposed ‘systemic microvascular paradigm’ has been used to explain HFpHF presentation heterogeneity. The lack of effective treatments with few evidence-based therapeutic recommendations makes HFpEF one of the greatest unmet clinical necessities worldwide. The endogenous levels of the purine nucleoside, adenosine, increase significantly following cardiovascular events. Adenosine exerts cardioprotective, neuromodulatory, and immunosuppressive effects by activating plasma membrane-bound P1 receptors that are widely expressed in the cardiovascular system. Its proven benefits have been demonstrated in preclinical animal tests. Here, we provide a comprehensive and up-to-date critical review about the main therapeutic advantages of tuning adenosine signalling pathways in HFpEF, without discounting their side effects and how these can be seized.

23 June 2025 in Netherlands Heart Journal
Verified
Journal Article
Open access
PDF file
BBBruno Bragança
Bruno Bragança
MMMauro Moreira
Mauro Moreira
RLRafaela G. Lopes
Rafaela G. Lopes
ICInês G. Campos
Inês G. Campos
JFJosé Luís Ferraro
José Luís Ferraro
AAAurora Andrade
Aurora Andrade
Background: Persistent congestion in heart failure (HF) carries a dismal prognosis. Bioimpedance analysis (BIA) non-invasively identifies extracellular water (ECW) redistribution associated with acute HF. However, its role in detecting subclinical congestion in HF outpatients still needs to be explored. Methods: Eighty-three adult outpatients with HFrEF were recruited for a single-center prospective study. Segmental multi-frequency BIA was used to assess body composition and the extracellular-to-total body water ratio (ECW/TBW), a marker of fluid redistribution. Subclinical congestion was defined as ECW/TBWz‑score > 2 without clinical signs of congestion. The primary outcome was a composite of all-cause death and worsening HF (WHF) events. Results: In this cohort, 57% of patients had subclinical congestion. Higher congestion grades were associated with age, female sex, and comorbidities. ECW/TBWz‑score correlated linearly with NT-proBNP levels and low muscular indexes were associated with congestion severity. During a median follow-up of 10 months, 27% of patients experienced the primary outcome, mostly WHF events. Both subclinical and clinical congestion were independently associated with an increased risk of the primary outcome, with hazard ratios (HR) of 9.4 (1.04–85.1; p = 0.046) and 17 (1.11–261; p = 0.042), respectively. NT-proBNP and ECW/TBWz‑score showed similar power in predicting the outcome. Conclusions: BIA detects subclinical congestion—a condition highly prevalent in outpatients with HFrEF. An increased ECW/TBW ratio correlates with established markers of congestion and is associated with adverse events in this population. These findings support the integration of BIA into routine HF care; however, further studies are needed to establish the clinical benefits of BIA-guided management and its impact on patient outcomes.

24 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MOMaria Isilda Oliveira
Maria Isilda Oliveira
BBBruno Bragança
Bruno Bragança
JGJosé Manuel Rodrigues Gomes
José Manuel Rodrigues Gomes
MSMário Santos
Mário Santos
Background/Objectives: Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterized by fibrosis and vascular damage, significantly increasing the risk of heart failure (HF). Methods: This cross-sectional study included 61 SSc patients (92% female, mean age 63 ± 13 years), excluding those with pulmonary arterial hypertension, referred to a tertiary pulmonary hypertension center. HF stages were classified according to updated guidelines. Clinical, echocardiographic, hemodynamic, and functional capacity data were analyzed in relation to HF stages. Results: A total of 48% of patients had pre-symptomatic HF (5% stage A, 43% stage B), while 38% had symptomatic HF (stage C). Advanced HF stages were significantly associated with older age (p = 0.02) and multiorgan involvement (p = 0.045) but not with SSc subtype or autoantibodies. Structural and functional echocardiographic abnormalities were prevalent (77% and 10%, respectively). Markers of elevated ventricular filling pressure such as left atrial volume (p = 0.011) and E/e’ ratio (p = 0.03) correlated with HF severity. Functional impairment was observed with lower 6 min walk test (6MWT) distance (p = 0.017), reduced VO2 peak (p = 0.015), and increased VE/VCO2 slope (p = 0.002). Resting pulmonary artery wedge pressure did not correlate with HF stage (p = 0.93). VE/VCO2 slope and 6MWT were independently associated with HF severity. Conclusions: Preclinical and symptomatic HF are highly prevalent in SSc patients. HF staging was linked to disease severity, age, and cardiovascular risk factors. Functional capacity tests (6MWT and CPET) serve as valuable tools for HF risk stratification. These findings highlight the critical need for comprehensive cardiovascular assessment and targeted management strategies to mitigate HF progression in SSc patients.

31 January 2023 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
IOInes Oliveira
Ines Oliveira
RLRafaela Lopes
Rafaela Lopes
ICIsabel Cruz
Isabel Cruz
BBBruno Bragança
Bruno Bragança
JAJoão Azevedo
João Azevedo
AAAurora Andrade
Aurora Andrade

1 January 2026 in International Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
MSMariana Pereira Santos
Mariana Pereira Santos
SCSérgio Campos
Sérgio Campos
CGCatarina Gomes
Catarina Gomes
MTMaria Trepa
Maria Trepa
BBBruno Bragança
Bruno Bragança
MSMário Santos
Mário Santos
Pereira Santos M, et al. Int J Heart Fail. 2026 Jul;8(3):256-262. https://doi.org/10.36628/ijhf.2026.0016